

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Donovan)
U.S. Serial No.: 09/692,811)
Filed: October 20, 2000)
For: METHOD FOR TREATING)
ENDOCRINE DISORDERS)

Examiner:

Art Unit:

RECEIVED

JUN 04 2001

RECEIVED
CENTER 1000/2300

**SUPPLEMENTARY
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant provides with regard to the above-referenced patent application one copy of each of the two documents listed on the attached Form PTO-1449, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56.


While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that any such document is prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

Respectfully submitted,

Stephen Donovan
Stephen Donovan
Registration Number 33,433

Date: December 21, 2000

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249



U.S. Serial Number: 09/692,811
Filed: October 20, 2000



Docket No: 17324 (AP)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this Supplementary Information Disclosure Statement and any additional documents set forth as being enclosed herein are being deposited with the United States Postal Service on the date shown below, with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.

Maria Zirbes

Name of Person Mailing

Date: 12-21-00

Maria Zirbes
Signature of Person Mailing

RECEIVED
JAN 04 2001
TECH CENTER 1600/2000